<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cushing disease is caused by pituitary corticotropin (ACTH)-secreting tumors. These tumors are almost always benign and are usually microadenomas (ie, &lt;10 mm in diameter). In 30 to 40 percent, the microadenoma is so small that it is not detectable by magnetic resonance imaging (MRI), while in 10 to 15 percent a macroadenoma is present. Treatment is aimed first at the anterior pituitary gland.</p><p>The progressive stages of treatment that may be required to cure a patient of Cushing disease are shown in the figure  (<a class="graphic graphic_algorithm graphicRef76949" href="/d/graphic/76949.html" rel="external">algorithm 1</a>). Primary therapy consists of transsphenoidal surgery or pituitary irradiation. Patients who fail this first approach can be treated either by repeat transsphenoidal surgery, medical therapy, radiotherapy, or, as a final resort, surgical or medical adrenalectomy. An overview of transsphenoidal surgery and pituitary irradiation for the primary therapy of Cushing disease will be reviewed here. An overview of the management of Cushing syndrome, as well as medical therapy and surgical adrenalectomy for Cushing are reviewed separately. (See  <a class="medical medical_review" href="/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome"</a> and  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a> and  <a class="medical medical_review" href="/d/html/16322.html" rel="external">"Persistent or recurrent Cushing disease: Surgical adrenalectomy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TRANSSPHENOIDAL SURGERY</span><span class="headingEndMark"> — </span>For patients who have corticotroph micro- or macroadenomas, we recommend transsphenoidal surgery as initial treatment. When successful, the patient is cured and is eventually left with normal hypothalamic-pituitary-adrenal function [<a href="#rid1">1,2</a>]. Surgical techniques and results of transsphenoidal surgery for pituitary adenomas are also reviewed in a separate topic. (See  <a class="medical medical_review" href="/d/html/86683.html" rel="external">"Transsphenoidal surgery for pituitary adenomas and other sellar masses", section on 'Corticotroph adenomas'</a>.)</p><p>Magnetic resonance imaging (MRI) is performed preoperatively to try to locate the pituitary tumor. However, surgery should be performed even if a tumor is not visualized.</p><p class="headingAnchor" id="H616841"><span class="h2">Approach</span><span class="headingEndMark"> — </span>The operative approach varies. Traditionally, the procedure involved transsphenoidal exploration through either a sublabial or endonasal approach, followed by use of a high-powered microscope that allowed for binocular vision. More recently, use of an endoscope, which does not provide binocular vision, has been advocated but has not been definitively shown to be superior [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/86683.html" rel="external">"Transsphenoidal surgery for pituitary adenomas and other sellar masses", section on 'Comparison of microscopic versus endoscopic techniques'</a>.)</p><p class="headingAnchor" id="H616848"><span class="h2">Extent of surgery</span><span class="headingEndMark"> — </span>The extent of surgery varies. Ideally, the entire tumor is removed while normal pituitary tissue is left behind. However, in adult patients in whom a microadenoma cannot be identified at the time of surgery and for whom fertility is not an issue, 80 to 90 percent of the pituitary should be resected, leaving a small island attached to the stalk. (See  <a class="medical medical_review" href="/d/html/86683.html" rel="external">"Transsphenoidal surgery for pituitary adenomas and other sellar masses", section on 'Determination of the extent of resection'</a>.)</p><p class="headingAnchor" id="H616855"><span class="h2">Preoperative localization</span><span class="headingEndMark"> — </span>In general, tumors are localized by the preoperative MRI scan or by intraoperative exploration and observation by the surgeon.</p><p class="headingAnchor" id="H3"><span class="h3">MRI</span><span class="headingEndMark"> — </span>The decision to operate should not depend upon radiographic demonstration of the tumor. High-resolution, contrast-enhanced, thin-section computed tomography (CT) scans detect only approximately one-third of the microadenomas, which appear hypodense after contrast injection  (<a class="graphic graphic_diagnosticimage graphicRef64273" href="/d/graphic/64273.html" rel="external">image 1</a>) [<a href="#rid4">4-6</a>]. Because CT scans define bony structures better, the neurosurgeon may, on occasion, request them. (See  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome", section on 'Pituitary MRI'</a>.)</p><p>Coronal projections of high-resolution MRI at 1.5 T with gadolinium enhancement reveal microadenomas in approximately 60 percent of patients and have replaced CT for localization  (<a class="graphic graphic_diagnosticimage graphicRef75003" href="/d/graphic/75003.html" rel="external">image 2</a> and <a class="graphic graphic_diagnosticimage graphicRef50905" href="/d/graphic/50905.html" rel="external">image 3</a>) [<a href="#rid6">6,7</a>]. In one report, a modified technique known as "spoiled gradient recalled acquisition technique" had superior sensitivity compared with conventional, post-contrast, spin-echo technique (80 versus 49 percent, respectively) but a higher false positive rate (4 versus 2 percent) [<a href="#rid8">8</a>]. False-positive MRI scans can be obtained in 10 percent of subjects with no endocrine disorders [<a href="#rid9">9</a>], who may or may not have "nonfunctioning" microadenomas [<a href="#rid10">10</a>]. False negative scans can occur in patients with an empty sella [<a href="#rid11">11</a>]. Some microadenomas that cannot be visualized with preoperative MRI can be identified using intraoperative ultrasonography [<a href="#rid12">12</a>].</p><p>The preoperative radiographic demonstration of tumor improved the likelihood of cure in some but not all centers; other possible confounding factors such as technical experience might account for the differences:</p><p class="bulletIndent1"><span class="glyph">●</span>In one retrospective analysis of 54 patients with Cushing disease (26 with pituitary microadenoma on preoperative MRI and 28 with a normal MRI but confirmed pituitary origin of corticotropin [ACTH] secretion on bilateral petrosal sinus sampling), clinical outcome of transsphenoidal surgery was similar regardless of the preoperative MRI findings [<a href="#rid13">13</a>]. Early surgical success rates were 78 and 88 percent in the normal and abnormal MRI groups, respectively: a difference that was not statistically significant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second study of 167 patients with clear-cut microadenoma on MRI, 148 of 167 (88 percent) achieved remission, suggesting that imaging localization may improve outcome [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a third study, 183 of 185 (99 percent) with microadenomas on MRI had initial remission [<a href="#rid15">15</a>].</p><p></p><p class="headingAnchor" id="H75084633"><span class="h3">Inferior petrosal sinus sampling</span><span class="headingEndMark"> — </span>Measurement of ACTH gradients between the two sinuses during inferior petrosal venous sinus catheterization predicts the correct side of the pituitary tumor in 69 to 80 percent of patients with lateral tumors [<a href="#rid16">16-18</a>]. In the absence of a lesion on MRI, the gradient may be used to choose the side for initial exploration, but if no tumor is found, the other side must be explored. The role of inferior petrosal sinus sampling for localization is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome", section on 'Petrosal venous sinus catheterization'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Perioperative glucocorticoids</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Before surgery</strong> – Preoperative glucocorticoid replacement is not necessary unless cortisol production has been blocked completely by adrenal enzyme inhibitors. In this instance, the patient should be treated like a patient with adrenal insufficiency. (See  <a class="medical medical_review" href="/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a>.)</p><p></p><p class="bulletIndent1">Practice patterns are variable. Some surgeons do not administer glucocorticoids [<a href="#rid19">19</a>], while others give higher than normal glucocorticoid replacement intraoperatively and for one to three days postoperatively to avoid symptoms and signs of acute steroid withdrawal [<a href="#rid20">20</a>]. There have been no comparisons of the benefits of one or the other approach. One typical regimen is <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 0.5 mg every six hours for four doses only, eg, only 24 hours of glucocorticoid therapy.</p><p></p><p class="bulletIndent1">Perioperative glucocorticoid therapy entails virtually no risk for the patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>After surgery</strong> –<strong> </strong>Glucocorticoids must be stopped for 24 hours before serum cortisol can be measured to assess cure. Glucocorticoid replacement can be held for a few days, with careful observation for the development of adrenal insufficiency.</p><p></p><p class="bulletIndent1">Patients who meet the criteria for successful surgery are hypocortisolemic for up to 12 months after microadenomectomy and require glucocorticoid replacement therapy, which must be supplemented during stress. (See  <a class="medical medical_review" href="/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a>.)</p><p></p><p class="bulletIndent1">Occasional patients become anorectic and have generalized malaise and postural hypotension three or four days after surgery. These problems often respond to higher doses of glucocorticoid for several days.</p><p></p><p class="bulletIndent1">Other rare patients with longstanding, severe Cushing disease have such severe symptoms of glucocorticoid withdrawal that replacement doses of glucocorticoid are inadequate, and they temporarily require higher doses, up to twofold higher. Both clinician and patient must recognize that administration of such doses constitutes iatrogenic hypercortisolism. Every effort should be made to taper to a replacement dose, ideally within a few weeks.</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Surgical complications</span></p><p class="headingAnchor" id="H616877"><span class="h3">Arginine vasopressin deficiency</span><span class="headingEndMark"> — </span>Transient, arginine vasopressin deficiency (AVP-D, previously called central diabetes insipidus) is common and was reported at a rate of 22 percent in a single institution with a high volume of pituitary surgery [<a href="#rid21">21</a>]. In contrast, permanent AVP-D occurs in only a few percent of patients, even among those who have subtotal resection of the gland, although more extensive resection may increase the incidence of permanent AVP-D to as much as 25 percent. (See  <a class="medical medical_review" href="/d/html/2381.html" rel="external">"Evaluation of patients with polyuria"</a> and  <a class="medical medical_review" href="/d/html/2313.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Treatment"</a>.)</p><p>Permanent AVP-D is typically accompanied by impaired secretion of other anterior pituitary hormones, particularly thyroid-stimulating hormone (TSH) [<a href="#rid22">22</a>]. In a survey answered by 958 neurosurgeons, anterior pituitary insufficiency was cited as a complication of transsphenoidal hypophysectomy in 19 percent of cases [<a href="#rid23">23</a>].</p><p>Hyponatremia occurs in 8 to 24 percent of patients, presenting from postoperative day 1 to 10, with maximal antidiuresis at day 7 [<a href="#rid20">20,24</a>]. In one study of 52 patients without AVP-D, 7 percent had symptomatic hyponatremia (plasma sodium &lt;125 mmol/L) with nausea, headache, and/or emesis [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H616884"><span class="h3">Other</span><span class="headingEndMark"> — </span>Other complications, apart from surgically related morbidity, include venous thrombosis and infection, which occurred in four and one patients, respectively, of 105 studied retrospectively [<a href="#rid25">25</a>]. Since the risk of thromboembolic complications is increased in Cushing syndrome, perioperative prophylaxis seems warranted in patients who are not ambulatory within a few days of surgery [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome", section on 'Thromboembolic events'</a>.)</p><p class="headingAnchor" id="H617476"><span class="h2">Is the patient cured?</span></p><p class="headingAnchor" id="H3728166625"><span class="h3">Rates</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adults</strong> – There is no consensus on the criteria for "cure" after transsphenoidal surgery for Cushing disease. When judged in the immediate postoperative period, adult patients with persistent elevations in urine cortisol are not in remission. However, the remaining patients show a spectrum of biochemical features ranging from hypoadrenalism, with undetectable serum cortisol and plasma ACTH concentrations, to apparently normal ACTH and cortisol levels.</p><p></p><p class="bulletIndent1">When judged by long-term outcome, patients with a postoperative serum cortisol less than 50 nmol/L (1.8 mcg/dL) have the highest long-term remission rates, 85 to 100 percent [<a href="#rid27">27-29</a>]. As noted, initial cure rates of up to 80 to 90 percent after transsphenoidal microadenectomy, based on postoperative serum cortisol concentrations &lt;5 mcg/dL (138 nmol/L) within 14 days of surgery, have been reported [<a href="#rid30">30-34</a>]. In two studies, long-term remission rates were 65 and 80 percent in patients judged by this less stringent postoperative criterion [<a href="#rid34">34,35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong> – Similar surgical cure rates have been observed in children [<a href="#rid36">36-38</a>].</p><p></p><p class="bulletIndent1">In one series of 42 children, remission occurred in 35 (83 percent), 26 of whom were carefully followed for a mean of 7.2 years. Seven subsequently relapsed after an average of 4.2 years [<a href="#rid38">38</a>]. Overall, pituitary surgery performed once or twice resulted in a long-term remission in approximately 80 percent of children.</p><p></p><p class="bulletIndent1">In another series of 72 children, 70 achieved initial and 66 of 72 (92 percent) achieved long-term remission during follow-up of 24 to 120 months [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Macroadenomas</strong> – In general, patients with macroadenomas have lower cure rates.</p><p></p><p class="bulletIndent1">As an example, of 137 patients with microadenomas operated on at a single center, 123 (90 percent) were cured initially. Of those, seven (6 percent) had a recurrence during a mean follow-up period of six years (range 1 to 11 years) [<a href="#rid40">40</a>]. Seventeen patients had macroadenomas, of whom 11 (65 percent) were cured initially; 3 of the 11 (27 percent) later had a recurrence.</p><p></p><p class="bulletIndent1">In another study, initial remission was reported in five of eight patients with macroadenomas extending beyond the sella (63 percent) and in 43 of 52 with intrasellar macroadenomas (83 percent) [<a href="#rid41">41</a>]. Both of these studies defined surgical cure as a postoperative serum cortisol &lt;5 mcg/dL (138 nmol/L).</p><p></p><p class="bulletIndent1">In contrast, the cure rate (after surgery alone) in a series of 18 macroadenomas was only 12.5 percent when the more stringent criterion described above was used (serum cortisol &lt;1.8 mcg/dL [50 nmol/L]) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late remission</strong> – Some patients appear to have a late remission, and early postoperative assessment of serum cortisol concentration is not sufficient to predict outcome, as illustrated by the following observations:</p><p></p><p class="bulletIndent1">Some patients show a gradual decline in cortisol during the first three months after surgery, possibly indicating progressive necrosis of remaining tumor cells. This was illustrated in a study of 17 patients whose serum cortisol remained higher than 50 nmol/L (1.8 mcg/dL) within the first 14 days after surgery. However, serum cortisols had decreased to &lt;50 nmol/L (1.8 mcg/dL) by three months after surgery, and all remained in remission during one to eight years of follow-up [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1">In a second study, 5.6 percent of 620 patients had late remission occurring at 38±50 days, suggesting that decisions about additional therapy should await additional testing in patients with persistent hypercortisolism after transsphenoidal surgery [<a href="#rid44">44</a>].</p><p></p><p class="headingAnchor" id="H1734115867"><span class="h3">Biochemical criteria</span><span class="headingEndMark"> — </span>A variety of criteria have been used to assess cure after transsphenoidal surgery [<a href="#rid45">45</a>]. The suggestions below apply only to those patients with active hypercortisolism at the time of surgery. The normal corticotropes in eucortisolemic patients on medical therapy (or those with symptom remission on glucocorticoid receptor blockers) or with mild or cyclic hypercortisolism may have recovered from previous inhibition, leading to normal cortisol levels after total tumor resection. In these patients, tests for the initial diagnosis of Cushing syndrome must be used to infer remission. (See  <a class="medical medical_review" href="/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a>.)</p><p>We currently suggest the following approach to assessing patient outcome in patients with active hypercortisolism:</p><p>Serum cortisol should be measured at 8 AM at least 24 hours after the last physiologic dose of glucocorticoid, beginning three to seven days after surgery, to assess cure [<a href="#rid46">46</a>]. Ideally, measurements are obtained for three consecutive days without glucocorticoid therapy.</p><p>The best criteria of cure are:</p><p class="bulletIndent1"><span class="glyph">●</span>An undetectable serum cortisol concentration</p><p class="bulletIndent1"><span class="glyph">●</span>An undetectable plasma ACTH concentration</p><p></p><p>Although an extremely low serum cortisol concentration (&lt;1.8 mcg/dL, 50 nmol/L) is the best predictor of cure, some patients with low but detectable serum cortisol concentrations (2 to 4 mcg/dL [55 to 110 nmol/L]) that suppress with low-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> may remain in remission [<a href="#rid46">46</a>], as may those with cortisol values &lt;5 mcg/dL (138 nmol/L) [<a href="#rid34">34,35</a>].</p><p>However, a persistently detectable serum cortisol concentration, even though it represents a major decrease from the preoperative concentration and is well within the normal range, may represent incomplete resection and an increased risk of recurrence. In these patients, measurement of cortisol every one to two weeks for up to three months may reveal a decline to less than 50 nmol/L (1.8 mcg/dL) [<a href="#rid43">43</a>]. Patients without a fully suppressed postoperative cortisol concentration may require some glucocorticoid replacement; ideally, this is 10 mg or less of <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> daily in the morning to avoid suppression of corticotropes. The blood sample is obtained before the morning hydrocortisone dose is taken. If the serum cortisol concentration becomes undetectable, the patient is considered cured.</p><p>Measurement of 24-hour urinary cortisol excretion may be useful since it confirms the serum cortisol concentration. The urine collection should begin at least 24 hours after the last small dose (10 mg or less) of <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a>; a small maintenance dose (0.25 to 0.5 mg) of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> may be substituted before and during the collection. Excretion of less than &lt;10 mcg/day (28 nmol/day) is consistent with cure.</p><p>Management of patients with intermediate postoperative values of serum or plasma cortisol should be individualized. If there is a reason to suspect that tumor tissue was left behind and that the normal values reflect tumor ACTH secretion, measurement of salivary cortisol at midnight can be helpful as it is likely to be abnormal with persistent disease. Lack of cortisol suppression to the overnight 1 mg <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test may help confirm the suspicion of persistent disease. In these cases, additional therapy may be recommended. Patients with normal cortisol dynamics, in whom the normal corticotropes may not be suppressed, may be followed.</p><p>ACTH, CRH, or <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> stimulation tests are not helpful in these patients, because it is not clear how to interpret the results in this setting. A persistent response of cortisol and ACTH to the administration of intravenous <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (10 mcg) may suggest a higher risk of recurrence [<a href="#rid47">47-49</a>]. (See  <a class="medical medical_review" href="/d/html/158.html" rel="external">"Desmopressin (DDAVP) stimulation test", section on 'Evaluating for remission of Cushing disease'</a>.)</p><p class="headingAnchor" id="H1921601861"><span class="h3">Factors that impact outcome</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurosurgeon experience </strong>–<strong> </strong>A neurosurgeon experienced with transsphenoidal surgery for Cushing patients can achieve an initial cure rate of 80 to 90 percent with microadenomas [<a href="#rid30">30,31,36,40,50-53</a>], but less than 60 percent with macroadenomas [<a href="#rid40">40,54</a>], although initial cure of 11 of 12 patients (92 percent) was reported from one center [<a href="#rid55">55</a>]. A meta-analysis of 18 reports since 1995 showed an overall initial cure rate for micro- and macroadenomas combined of 79 percent [<a href="#rid56">56</a>]. It is important to recognize that patients who are initially "cured" should be considered to be in remission rather than cured, as some will recur. (See  <a class="medical medical_review" href="/d/html/86683.html" rel="external">"Transsphenoidal surgery for pituitary adenomas and other sellar masses", section on 'Corticotroph adenomas'</a>.)</p><p></p><p class="bulletIndent1">Less experienced neurosurgeons may have a cure rate as low as zero [<a href="#rid32">32</a>]. The cure rates with microadenomas depend upon pathologic confirmation of an adenoma or unequivocal demonstration of cure after resection, since approximately one-half of these tumors cannot be imaged in advance of surgery [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/d/html/86683.html" rel="external">"Transsphenoidal surgery for pituitary adenomas and other sellar masses", section on 'Experience of the surgeon'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical approach</strong> – It is likely that the approach to tumor resection influences the cure rate. In one study of 483 patients, 261 (54 percent) were considered intraoperatively to have an encapsulated adenoma confined to the anterior lobe of the pituitary gland; 166 (34 percent) had tumors invading the dura surrounding the pituitary; 11 (2 percent) had tumors within the posterior lobe; and in 45 (9 percent), no tumor could be identified at surgery. Remission occurred in 147 (89 percent) of the 166 patients with invasive tumors following resection that included the tumor and dural wall, all 11 patients with posterior lobe tumors following exploration of the posterior pituitary, and 34 (76 percent) of the 45 patients in whom no tumor could be found at surgery and a portion of the anterior lobe (30 to 100 percent) was removed. All 261 patients with an encapsulated adenoma had remission, following use of the histological tumor pseudocapsule so that the tumor is removed in a single specimen [<a href="#rid15">15</a>]. Increased use of the pseudocapsule approach may improve cure rates at other centers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Location and features of the adenoma</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All of the contents of the sella cannot be seen at surgery, so that some adenoma tissue may be missed. Diligent exploration of the entire gland is optimal if tumor is not recognized initially.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse corticotroph hyperplasia may be present. However, this is extremely rare.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The adenoma may arise in the pituitary stalk, which is not readily accessible to the surgeon. This occurred in 10 of 516 patients in one series, although all were successfully removed, with preservation of pituitary function in nine [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adenomas that arise on the surface of the gland tend to be locally invasive; tumor cells in the interstices of the dura mater or in the cavernous sinus cannot be surgically excised [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rarely, adenomas arising in ectopic sites may be the cause [<a href="#rid60">60,61</a>]. In one series of 626 patients with Cushing disease, five patients (0.8 percent) had parasellar tumors; a sixth patient appeared to have two distinct ACTH-secreting corticotroph adenomas, one in the periphery of the pituitary gland and the other in the cavernous sinus [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ACTH-secreting adenomas may rarely be located within the posterior lobe of the pituitary gland [<a href="#rid63">63</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Recurrence</span><span class="headingEndMark"> — </span>The true long-term cure rate is not known with certainty, in part because of differing criteria for cure and also because of inadequate follow-up [<a href="#rid28">28,29,34,35,37,43,64-67</a>].</p><p>The average reported interval to recurrence is approximately 40 months. However, this figure is in part an artifact of the relatively short duration of follow-up of many patients. One study prospectively analyzed the recurrence rate in 79 cured patients by survival analysis; 19 percent had recurrences by five years, and the cumulative recurrence rate was 26 percent at 10 years [<a href="#rid67">67</a>]. Others have reported a similar recurrence rate of 22 percent in 45 patients at a mean follow-up of nine years [<a href="#rid68">68</a>].</p><p>There is a similar time-to-recurrence in children; the average interval in seven children was 4.2 years (nine months to 6.2 years) [<a href="#rid38">38</a>].</p><p>The likelihood of recurrence can be predicted only in part by postoperative serum cortisol measurements. As an example, a recurrence rate as high as 12 percent was reported in patients with undetectable postoperative cortisol levels [<a href="#rid29">29</a>]. Complete normalization of adrenocortical function may be a better predictor of outcome. As an example, in one study of patients after transsphenoidal surgery, those who had low postsurgery serum cortisol concentrations and subsequent recovery of normal circadian rhythm and responsiveness to insulin-induced hypoglycemia had much lower recurrence rates (3.4 percent) than those who did not recover normal hypothalamic-pituitary-adrenal function (50 to 65 percent) [<a href="#rid27">27</a>].</p><p>Other hormone tests also provide prognostic information. In one report, for example, the recurrence rate increased from 11 percent in patients who had postoperative urinary cortisol values of 20 mcg/day (56 nmol/day) or less to 36 percent when the value was above 35 mcg/day (96 nmol/day; normal range 20 to 48 mcg/day [55 to 331 nmol/day]). Similarly, the recurrence rate increased from 8 percent in patients with a plasma ACTH concentration of 20 pg/mL (4.4 pmol/L) or less to 53 percent in those with a plasma ACTH concentration of 35 pg/mL (7.7 pmol/L) or more (normal range up 100 pg/mL [22 pmol/L]) [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Long-term monitoring</span><span class="headingEndMark"> — </span>All patients should be reevaluated annually for several years and less frequently thereafter. This is particularly true in those who had initial intermittent hypersecretion of cortisol; these patients may seem to be cured after surgery but continue to secrete excess cortisol intermittently [<a href="#rid69">69</a>]. Reevaluation should include measurements of late-night salivary cortisol, a 24-hour urinary cortisol, and/or the 1 mg <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test [<a href="#rid65">65</a>], using the same criteria as for diagnosis (see  <a class="medical medical_review" href="/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a>). Patients should be encouraged to consider reevaluation at any time if they experience a return of their initial symptoms.</p><p class="headingAnchor" id="H13"><span class="h2">Treatment if surgery fails</span><span class="headingEndMark"> — </span>For patients with clear, persistent disease after surgery (elevated urine cortisol excretion), one must first review the pathology results. If a tumor is not present on pathology, it is prudent to review the results of the tests for the differential diagnosis. In one study, 5 of 52 patients who failed surgery were found to have ectopic ACTH secretion [<a href="#rid52">52</a>]. In patients with equivocal results, additional testing may be needed.</p><p>Five therapeutic options remain in patients who are not cured in whom the diagnosis of Cushing disease appears to be correct:</p><p class="bulletIndent1"><span class="glyph">●</span>Repeat resection of residual corticotroph adenoma, particularly if residual tumor is visible on MRI. Reoperation has a lower success rate than initial surgery. In three studies, 57 to 71 percent of patients who underwent early reoperation had evidence of biochemical cure [<a href="#rid33">33,70,71</a>]. However, many of them developed other pituitary hormone deficiencies as a result of the second procedure. In one study, immediate reoperation was most successful when the pathology indicated incomplete resection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Irradiation of the pituitary gland. (See <a class="local">'Pituitary irradiation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical therapy. (See  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adrenalectomy – Medical or surgical.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medical adrenalectomy with <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a>, for example, may be used in conjunction with pituitary irradiation  (<a class="graphic graphic_algorithm graphicRef76949" href="/d/graphic/76949.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)", section on 'Mitotane'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgical adrenalectomy. (See  <a class="medical medical_review" href="/d/html/16322.html" rel="external">"Persistent or recurrent Cushing disease: Surgical adrenalectomy", section on 'Surgical adrenalectomy'</a>.)</p><p></p><p>The choice for therapy is individualized. For example, a young woman desiring fertility might choose to have adrenalectomy or repeat transsphenoidal exploration to avoid hypogonadism associated with radiotherapy and the teratogenicity of <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a>. A patient with extreme hypercortisolism might choose adrenalectomy to achieve rapid control.</p><p class="headingAnchor" id="H14"><span class="h1">PITUITARY IRRADIATION</span><span class="headingEndMark"> — </span>Pituitary irradiation is the rational choice when pituitary surgery is either not the initial therapy or has failed. In addition, it may be considered as the initial therapy in children because it is as successful as transsphenoidal surgery [<a href="#rid38">38,72,73</a>].</p><p>The principal goal is to lower corticotropin (ACTH) secretion and thereby lower cortisol secretion to normal.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type of radiation</strong> – Stereotactic radiosurgery (20 to 25 Gy) is considered the first choice if the adenoma is not close to the optic pathway; fractionated radiation (50.4 to 54 Gy) is used for those that are [<a href="#rid74">74-79</a>]. Stereotactic radiosurgery may be targeted when a pathologically confirmed lesion was partially resected; when the location of the tumor is not known, the entire sella must be radiated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Reduction of cortisol to normal occurs in 50 to 80 percent of subjects. Addition of pharmacologic therapy increases the remission rates to 85 to 100 percent. Normalization of cortisol may occur somewhat faster after stereotactic radiosurgery than fractionated therapy, a median of 7.5 to 33 months versus 18 to 42 months [<a href="#rid80">80</a>]. Efficacy appears similar among all forms of stereotactic radiosurgery: Gamma Knife [<a href="#rid74">74</a>], linear accelerator [<a href="#rid78">78</a>], and proton [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenal enzyme inhibitors</strong> – Patients with hypercortisolism should receive adrenal enzyme inhibitors (such as <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a>, <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a>, or <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>) to achieve eucortisolism until the radiation therapy is successful [<a href="#rid1">1</a>]. The ability of these agents to achieve eucortisolism should be evaluated prior to radiation therapy. If they are not effective, a different treatment should be considered. (See  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Control of adenoma growth</strong> – A second goal of radiation therapy is control of adenoma growth, especially in corticotroph macroadenomas. All modalities of radiation therapy control adenoma growth in 90 to 100 percent of patients [<a href="#rid74">74,76-78</a>], similar to nonfunctioning adenomas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nelson syndrome</strong> – Corticotroph adenomas associated with Nelson syndrome may be less responsive to radiation than other corticotroph adenomas, but the data are limited [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determine efficacy</strong> – To judge the effectiveness of radiation therapy, steroidogenesis inhibitor(s) can be stopped for a few days and 24-hour urine cortisol measured. Patients should receive teaching about adrenal insufficiency symptoms and should be instructed to return to the clinician if they experience such symptoms.</p><p></p><p class="headingAnchor" id="H132835060"><span class="h2">Fractionated radiation</span><span class="headingEndMark"> — </span>A total of 42 to 45 Gy (4200 to 4500 rad) of conventional megavoltage radiation is delivered to the pituitary gland at a rate of 1.8 to 2 Gy/day (180 to 200 rad/day), usually via multiple collimated ports using a linear accelerator.</p><p class="headingAnchor" id="H617067"><span class="h3">Primary therapy</span><span class="headingEndMark"> — </span>The results of fractionated pituitary radiation as primary treatment can be summarized as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 80 percent of children are cured [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cure rate in adults is 15 to 53 percent [<a href="#rid1">1,81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another 25 to 30 percent of adults are sufficiently improved that they require no additional therapy or only small doses of an adrenal enzyme inhibitor [<a href="#rid1">1</a>].</p><p></p><p>In contrast to the almost immediate reduction in ACTH and cortisol secretion after successful pituitary surgery, the maximal benefits of pituitary radiation do not occur for at least 9 to 12 months and occasionally as long as 18 to 24 months. Occasional "improved" patients may be cured several years after treatment. Children usually respond more rapidly, often within three months [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H617074"><span class="h3">Secondary therapy</span><span class="headingEndMark"> — </span>The percent of patients responding to fractionated radiation therapy may be somewhat higher after failed transsphenoidal surgery [<a href="#rid75">75,82</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>As an example, one study evaluated the efficacy of somewhat higher doses of radiation (48 to 54 Gy, mean 50 Gy) in 30 adults with persistent or recurrent Cushing disease after unsuccessful transsphenoidal surgery [<a href="#rid75">75</a>]. The remission rate increased progressively with time from 20 percent at six months to 43 percent at 12 months to 83 percent at 60 months. None of the 25 patients who were cured had a relapse of Cushing disease after remission was achieved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of 40 patients, 32 achieved remission at a follow-up interval of nine years [<a href="#rid76">76</a>].</p><p></p><p class="headingAnchor" id="H16"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Serious side effects are rare in either adults or children with the treatment schedule described above given as primary therapy [<a href="#rid1">1,83</a>]. (See  <a class="medical medical_review" href="/d/html/86684.html" rel="external">"Radiation therapy of pituitary adenomas", section on 'Risks/adverse effects'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Less than 5 percent of the patients developed clinical growth hormone or thyroid-stimulating hormone (TSH) deficiency, sometimes years after radiation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With provocative testing, some degree of pituitary deficiency has been detected in a majority of patients who receive two to three times the currently recommended fractional dose [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypopituitarism was more frequent in the reports described above in patients with failed transsphenoidal surgery [<a href="#rid75">75,76</a>]. In these studies, 43 to 57 percent of the patients had growth hormone deficiency and approximately 33 percent had deficiencies of one or more other pituitary hormones. In one study of children, five of six who received both transsphenoidal surgery and radiation developed growth hormone deficiency, which was transient in two [<a href="#rid85">85</a>].</p><p></p><p>There is a longstanding controversy regarding a possible increased risk of death from cerebrovascular disease after radiation therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>A long-term, follow-up study of 342 patients with pituitary tumors (mostly nonsecreting tumors) treated by surgery and radiation suggested that radiation per se is not responsible for these deaths. The characteristics of radiation were not different in the cerebrovascular deaths (31 patients), compared with a control group that received radiation but did not have a cerebrovascular event [<a href="#rid86">86</a>]. Patients with Cushing disease (and acromegaly) were excluded from this study because of the increased incidence of cerebrovascular complications in these patients irrespective of the mode of therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second study, 33 of 334 patients with pituitary adenoma died of cerebrovascular disease after radiation therapy, representing an increased relative risk of 4.11 compared with national age, sex, and interval mortality rates [<a href="#rid87">87</a>].</p><p></p><p>Higher cure rates can be attained by delivering up to 110 Gy (11,000 rad) of alpha-particle or proton beam external radiation over a few days [<a href="#rid88">88,89</a>] or 198Au or 90Y interstitial radiation [<a href="#rid90">90,91</a>]. These regimens, however, are associated with a higher incidence of side effects, especially hypopituitarism.</p><p class="headingAnchor" id="H17"><span class="h2">Stereotactic radiosurgery</span><span class="headingEndMark"> — </span>Stereotactic radiosurgery with the 60Co Gamma Knife or the linear accelerator photon knife is another treatment option [<a href="#rid92">92,93</a>]. These instruments can deliver over 100 Gy (10,000 rad) of radiation with great precision in one treatment session  (<a class="graphic graphic_diagnosticimage graphicRef64369 graphicRef76201" href="/d/graphic/64369.html" rel="external">image 4A-B</a>). (See  <a class="medical medical_review" href="/d/html/7063.html" rel="external">"Stereotactic cranial radiosurgery"</a>.)</p><p class="headingAnchor" id="H2692249067"><span class="h3">Results of primary therapy</span><span class="headingEndMark"> — </span>In one series, 89 patients aged 5 to 67 with ACTH-producing tumors were treated with stereotactic radiosurgery, and 18 were followed for 12 to 22 years [<a href="#rid94">94</a>]. Of the 89 patients, 64 received one, and 25 had two or more courses of treatment. There were no treatment-related deaths, and vision and visual fields were not affected. Urinary cortisol levels gradually normalized in 83 percent, and no tumor recurrences were noted.</p><p class="headingAnchor" id="H236289590"><span class="h3">Results of secondary therapy</span><span class="headingEndMark"> — </span>In a study of Gamma Knife after failed transsphenoidal surgery, 49 of 90 patients (54 percent) were cured, as indicated by normal urine cortisol excretion, on average approximately one year after treatment [<a href="#rid74">74</a>]. Ten patients (20 percent) had subsequent recurrence of hypercortisolism within five years.</p><p class="headingAnchor" id="H3257454819"><span class="h3">Side effects of stereotactic radiotherapy</span><span class="headingEndMark"> — </span>As with conventional fractionated radiotherapy, hypopituitarism is the most common side effect of radiosurgery.</p><p class="bulletIndent1"><span class="glyph">●</span>In the series of 89 patients mentioned above, two-thirds developed radiation-induced endocrine deficiencies, some as late as 10 years after treatment [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the series of 90 patients mentioned above, 20 (22 percent) developed new hormonal deficiencies. Five patients developed new visual deficits or third, fourth, or sixth cranial nerve deficits; two of these patients had undergone prior conventional fractionated radiation therapy, and four of them had received previous Gamma Knife therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other studies have shown that when side effects do arise with stereotactic radiation, they may occur within two years of treatment [<a href="#rid95">95</a>], although the median time is five years [<a href="#rid96">96</a>].</p><p></p><p>Stereotactic radiosurgery is more convenient for patients as it requires only one or two treatments, but it is generally more expensive than conventional radiation therapy (in the United States). There are not sufficient data to know if the side-effect profile differs between the two.</p><p class="headingAnchor" id="H18"><span class="h1">RESOLUTION OF CUSHING STIGMATA</span><span class="headingEndMark"> — </span>In patients who are cured of Cushing disease or whose hypercortisolism is controlled, signs and symptoms of hypercortisolism improve rapidly and disappear over a period of 2 to 12 months. Thinning of the skin improves within weeks; muscle strength improves more slowly. Central obesity is usually lost, whereas patients with generalized obesity, especially if sustained for years rather than months, usually have difficulty losing the additional weight. Hypertension and glucose intolerance improve but may not be cured.</p><p>Unlike other forms of osteoporosis, the osteoporosis of Cushing syndrome improves rapidly during the first two years after cure and more gradually thereafter [<a href="#rid97">97</a>]. Unfortunately, vertebral compression fractures and aseptic necrosis of the proximal humerus and femur cause permanent deformity and are a major incentive for early cure of Cushing syndrome.</p><p>Five years after cure, 15 patients in one study had a higher prevalence of atherosclerosis and increased cardiovascular risk factors, probably due to residual abdominal obesity and insulin resistance [<a href="#rid82">82</a>]. Similar findings were reported in a study of 41 patients who had a higher prevalence of obesity and dyslipidemia than case controls at a mean follow-up duration of 11 years [<a href="#rid98">98</a>].</p><p>Resolution of neuropsychiatric symptoms after surgery is variable. (See  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome", section on 'Neuropsychologic changes and cognition'</a>.)</p><p class="headingAnchor" id="H460303475"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112709.html" rel="external">"Society guideline links: Diagnosis and treatment of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H1196735"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15600.html" rel="external">"Patient education: Cushing syndrome (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2173.html" rel="external">"Patient education: Cushing syndrome (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2177.html" rel="external">"Patient education: Cushing syndrome treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H616954"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cushing disease</strong> – Cushing disease is caused by pituitary corticotropin (ACTH)-secreting tumors. These tumors are almost always benign and are usually microadenomas (ie, &lt;10 mm in diameter); in 30 to 40 percent, the microadenoma is so small that it is not detectable by magnetic resonance imaging (MRI), while in 10 to 15 percent, a macroadenoma is present. Treatment is aimed first at the anterior pituitary gland.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transsphenoidal surgery</strong> – For most adult patients with Cushing disease, we suggest transsphenoidal surgery with an experienced surgeon as primary therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Transsphenoidal surgery'</a> above.)</p><p></p><p class="bulletIndent1">The operative approach varies. Traditionally, the procedure involved transsphenoidal exploration through either a sublabial or endonasal approach, followed by use of a high-powered microscope that allowed for binocular vision. More recently, use of an endoscope, which does not provide binocular vision, has been advocated.</p><p></p><p class="bulletIndent1">The extent of surgery varies. Ideally, the entire tumor is removed, while normal pituitary tissue is left behind. However, in adult patients in whom a microadenoma cannot be identified at the time of surgery and for whom fertility is not an issue, 80 to 90 percent of the pituitary should be resected, leaving a small island attached to the stalk.</p><p></p><p class="bulletIndent1">The main surgical complication is arginine vasopressin deficiency (AVP-D), which occurs transiently in up to approximately 20 percent of patients but is rarely permanent. (See <a class="local">'Arginine vasopressin deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biochemical assessment for cure</strong> – Serum cortisol should be measured at 8 AM at least 24 hours after the last physiologic dose of glucocorticoid, beginning two to seven days after surgery, to assess cure. Ideally, measurements are obtained for three consecutive days without glucocorticoid therapy. Although an extremely low serum cortisol concentration (&lt;1.8 mcg/dL [50 nmol/L]) is the best predictor of cure, there are exceptions to this as described above. (See <a class="local">'Biochemical criteria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term monitoring</strong> – All patients should be reevaluated annually for several years and less frequently thereafter. This is particularly true for those who had intermittent hypersecretion of cortisol initially; these patients may seem to be cured after surgery but continue to secrete excess cortisol intermittently. (See <a class="local">'Long-term monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management if surgery fails</strong> – The presence of tumor on pathology and the previous testing should be examined to ensure that the diagnosis is correct. If only a part of the tumor has been resected, immediate repeat surgery is an option. (See <a class="local">'Treatment if surgery fails'</a> above.)</p><p></p><p class="bulletIndent1">For patients with a secure diagnosis in whom surgery has failed and with little or no radiologically detectable residual tumor, we suggest radiation therapy as the next step (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In patients with mild disease in whom the possibility of an additional two to four months of hypercortisolism is not deemed too risky, medical therapy with <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> or <a class="drug drug_general" data-topicid="87457" href="/d/drug information/87457.html" rel="external">pasireotide</a> is an alternative, recognizing that it is successful in only a minority of individuals. Radiation with adjunctive medical therapy may be best in those with dural invasion or who have unresectable remaining tumor. Adrenalectomy may be favored in those with severe hypercortisolism who need immediate cure or in women desiring pregnancy in whom steroidogenesis inhibitors are contraindicated.</p><p></p><p class="headingAnchor" id="H303203018"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Orth DN, Liddle GW. Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med 1971; 285:243.</a></li><li><a class="nounderline abstract_t">Khan DZ, Hanrahan JG, Baldeweg SE, et al. Current and Future Advances in Surgical Therapy for Pituitary Adenoma. Endocr Rev 2023; 44:947.</a></li><li><a class="nounderline abstract_t">Porterfield JR, Thompson GB, Young WF Jr, et al. Surgery for Cushing's syndrome: an historical review and recent ten-year experience. World J Surg 2008; 32:659.</a></li><li><a class="nounderline abstract_t">Marcovitz S, Wee R, Chan J, Hardy J. The diagnostic accuracy of preoperative CT scanning in the evaluation of pituitary ACTH-secreting adenomas. AJR Am J Roentgenol 1987; 149:803.</a></li><li><a class="nounderline abstract_t">Saris SC, Patronas NJ, Doppman JL, et al. Cushing syndrome: pituitary CT scanning. Radiology 1987; 162:775.</a></li><li><a class="nounderline abstract_t">Escourolle H, Abecassis JP, Bertagna X, et al. Comparison of computerized tomography and magnetic resonance imaging for the examination of the pituitary gland in patients with Cushing's disease. Clin Endocrinol (Oxf) 1993; 39:307.</a></li><li><a class="nounderline abstract_t">Dwyer AJ, Frank JA, Doppman JL, et al. Pituitary adenomas in patients with Cushing disease: initial experience with Gd-DTPA-enhanced MR imaging. Radiology 1987; 163:421.</a></li><li><a class="nounderline abstract_t">Patronas N, Bulakbasi N, Stratakis CA, et al. Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J Clin Endocrinol Metab 2003; 88:1565.</a></li><li><a class="nounderline abstract_t">Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120:817.</a></li><li><a class="nounderline abstract_t">Parent AD, Bebin J, Smith RR. Incidental pituitary adenomas. J Neurosurg 1981; 54:228.</a></li><li><a class="nounderline abstract_t">Lipkin EW, Fujimoto WY. Cushing's syndrome in a patient with suppressible hypercortisolism and an empty sella. West J Med 1984; 140:613.</a></li><li><a class="nounderline abstract_t">Ram Z, Shawker TH, Bradford MH, et al. Intraoperative ultrasound-directed resection of pituitary tumors. J Neurosurg 1995; 83:225.</a></li><li><a class="nounderline abstract_t">Salenave S, Gatta B, Pecheur S, et al. Pituitary magnetic resonance imaging findings do not influence surgical outcome in adrenocorticotropin-secreting microadenomas. J Clin Endocrinol Metab 2004; 89:3371.</a></li><li><a class="nounderline abstract_t">Prevedello DM, Pouratian N, Sherman J, et al. Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J Neurosurg 2008; 109:751.</a></li><li><a class="nounderline abstract_t">Jagannathan J, Smith R, DeVroom HL, et al. Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease. J Neurosurg 2009; 111:531.</a></li><li><a class="nounderline abstract_t">Liu C, Lo JC, Dowd CF, et al. Cavernous and inferior petrosal sinus sampling in the evaluation of ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 2004; 61:478.</a></li><li><a class="nounderline abstract_t">Batista D, Gennari M, Riar J, et al. An assessment of petrosal sinus sampling for localization of pituitary microadenomas in children with Cushing disease. J Clin Endocrinol Metab 2006; 91:221.</a></li><li><a class="nounderline abstract_t">Wind JJ, Lonser RR, Nieman LK, et al. The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing's disease. J Clin Endocrinol Metab 2013; 98:2285.</a></li><li><a class="nounderline abstract_t">Patil CG, Veeravagu A, Prevedello DM, et al. Outcomes after repeat transsphenoidal surgery for recurrent Cushing's disease. Neurosurgery 2008; 63:266.</a></li><li><a class="nounderline abstract_t">Olson BR, Rubino D, Gumowski J, Oldfield EH. Isolated hyponatremia after transsphenoidal pituitary surgery. J Clin Endocrinol Metab 1995; 80:85.</a></li><li><a class="nounderline abstract_t">Nemergut EC, Zuo Z, Jane JA Jr, Laws ER Jr. Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. J Neurosurg 2005; 103:448.</a></li><li><a class="nounderline abstract_t">Burke CW, Adams CB, Esiri MM, et al. Transsphenoidal surgery for Cushing's disease: does what is removed determine the endocrine outcome? Clin Endocrinol (Oxf) 1990; 33:525.</a></li><li><a class="nounderline abstract_t">Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997; 40:225.</a></li><li><a class="nounderline abstract_t">Hensen J, Henig A, Fahlbusch R, et al. Prevalence, predictors and patterns of postoperative polyuria and hyponatraemia in the immediate course after transsphenoidal surgery for pituitary adenomas. Clin Endocrinol (Oxf) 1999; 50:431.</a></li><li><a class="nounderline abstract_t">Semple PL, Laws ER Jr. Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing's disease. J Neurosurg 1999; 91:175.</a></li><li><a class="nounderline abstract_t">Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 2002; 87:3662.</a></li><li><a class="nounderline abstract_t">Estrada J, García-Uría J, Lamas C, et al. The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 2001; 86:5695.</a></li><li><a class="nounderline abstract_t">Newell-Price J. Transsphenoidal surgery for Cushing's disease: defining cure and following outcome. Clin Endocrinol (Oxf) 2002; 56:19.</a></li><li><a class="nounderline abstract_t">Yap LB, Turner HE, Adams CB, Wass JA. Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit. Clin Endocrinol (Oxf) 2002; 56:25.</a></li><li><a class="nounderline abstract_t">Salassa RM, Laws ER Jr, Carpenter PC, Northcutt RC. Transsphenoidal removal of pituitary microadenoma in Cushing's disease. Mayo Clin Proc 1978; 53:24.</a></li><li><a class="nounderline abstract_t">Carpenter PC. Cushing's syndrome: update of diagnosis and management. Mayo Clin Proc 1986; 61:49.</a></li><li><a class="nounderline abstract_t">Burch W. A survey of results with transsphenoidal surgery in Cushing's disease. N Engl J Med 1983; 308:103.</a></li><li><a class="nounderline abstract_t">Ram Z, Nieman LK, Cutler GB Jr, et al. Early repeat surgery for persistent Cushing's disease. J Neurosurg 1994; 80:37.</a></li><li><a class="nounderline abstract_t">Esposito F, Dusick JR, Cohan P, et al. Clinical review: Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 2006; 91:7.</a></li><li><a class="nounderline abstract_t">Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab 1995; 80:3114.</a></li><li><a class="nounderline abstract_t">Styne DM, Grumbach MM, Kaplan SL, et al. Treatment of Cushing's disease in childhood and adolescence by transsphenoidal microadenomectomy. N Engl J Med 1984; 310:889.</a></li><li><a class="nounderline abstract_t">Leinung MC, Kane LA, Scheithauer BW, et al. Long term follow-up of transsphenoidal surgery for the treatment of Cushing's disease in childhood. J Clin Endocrinol Metab 1995; 80:2475.</a></li><li><a class="nounderline abstract_t">Devoe DJ, Miller WL, Conte FA, et al. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 1997; 82:3196.</a></li><li><a class="nounderline abstract_t">Batista DL, Oldfield EH, Keil MF, Stratakis CA. Postoperative testing to predict recurrent Cushing disease in children. J Clin Endocrinol Metab 2009; 94:2757.</a></li><li><a class="nounderline abstract_t">Swearingen B, Biller BM, Barker FG 2nd, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 1999; 130:821.</a></li><li><a class="nounderline abstract_t">Hammer GD, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab 2004; 89:6348.</a></li><li><a class="nounderline abstract_t">Woo YS, Isidori AM, Wat WZ, et al. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 2005; 90:4963.</a></li><li><a class="nounderline abstract_t">Pereira AM, van Aken MO, van Dulken H, et al. Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J Clin Endocrinol Metab 2003; 88:5858.</a></li><li><a class="nounderline abstract_t">Valassi E, Biller BM, Swearingen B, et al. Delayed remission after transsphenoidal surgery in patients with Cushing's disease. J Clin Endocrinol Metab 2010; 95:601.</a></li><li><a class="nounderline abstract_t">Orth DN. Cushing's syndrome. N Engl J Med 1995; 332:791.</a></li><li><a class="nounderline abstract_t">McCance DR, Besser M, Atkinson AB. Assessment of cure after transsphenoidal surgery for Cushing's disease. Clin Endocrinol (Oxf) 1996; 44:1.</a></li><li><a class="nounderline abstract_t">Colombo P, Dall'Asta C, Barbetta L, et al. Usefulness of the desmopressin test in the postoperative evaluation of patients with Cushing's disease. Eur J Endocrinol 2000; 143:227.</a></li><li><a class="nounderline abstract_t">Romanholi DJ, Machado MC, Pereira CC, et al. Role for postoperative cortisol response to desmopressin in predicting the risk for recurrent Cushing's disease. Clin Endocrinol (Oxf) 2008; 69:117.</a></li><li><a class="nounderline abstract_t">Losa M, Mortini P, Dylgjeri S, et al. Desmopressin stimulation test before and after pituitary surgery in patients with Cushing's disease. Clin Endocrinol (Oxf) 2001; 55:61.</a></li><li><a class="nounderline abstract_t">Bigos ST, Somma M, Rasio E, et al. Cushing's disease: management by transsphenoidal pituitary microsurgery. J Clin Endocrinol Metab 1980; 50:348.</a></li><li><a class="nounderline abstract_t">Chandler WF, Schteingart DE, Lloyd RV, et al. Surgical treatment of Cushing's disease. J Neurosurg 1987; 66:204.</a></li><li><a class="nounderline abstract_t">Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med 1988; 109:487.</a></li><li><a class="nounderline abstract_t">Shimon I, Ram Z, Cohen ZR, Hadani M. Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 2002; 51:57.</a></li><li><a class="nounderline abstract_t">Aron DC, Findling JW, Fitzgerald PA, et al. Cushing's syndrome: problems in management. Endocr Rev 1982; 3:229.</a></li><li><a class="nounderline abstract_t">Fomekong E, Maiter D, Grandin C, Raftopoulos C. Outcome of transsphenoidal surgery for Cushing's disease: a high remission rate in ACTH-secreting macroadenomas. Clin Neurol Neurosurg 2009; 111:442.</a></li><li><a class="nounderline abstract_t">Kelly DF. Transsphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's Syndrome. Neurosurg Focus 2007; 23:E5.</a></li><li><a class="nounderline abstract_t">Bakiri F, Tatai S, Aouali R, et al. Treatment of Cushing's disease by transsphenoidal, pituitary microsurgery: prognosis factors and long-term follow-up. J Endocrinol Invest 1996; 19:572.</a></li><li><a class="nounderline abstract_t">Mason RB, Nieman LK, Doppman JL, Oldfield EH. Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function. J Neurosurg 1997; 87:343.</a></li><li><a class="nounderline abstract_t">Meij BP, Lopes MB, Ellegala DB, et al. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 2002; 96:195.</a></li><li><a class="nounderline abstract_t">Kammer H, George R. Cushing's disease in a patient with an ectopic pituitary adenoma. JAMA 1981; 246:2722.</a></li><li><a class="nounderline abstract_t">Wilson CB, Mindermann T, Tyrrell JB. Extrasellar, intracavernous sinus adrenocorticotropin-releasing adenoma causing Cushing's disease. J Clin Endocrinol Metab 1995; 80:1774.</a></li><li><a class="nounderline abstract_t">Pluta RM, Nieman L, Doppman JL, et al. Extrapituitary parasellar microadenoma in Cushing's disease. J Clin Endocrinol Metab 1999; 84:2912.</a></li><li><a class="nounderline abstract_t">Weil RJ, Vortmeyer AO, Nieman LK, et al. Surgical remission of pituitary adenomas confined to the neurohypophysis in Cushing's disease. J Clin Endocrinol Metab 2006; 91:2656.</a></li><li><a class="nounderline abstract_t">Guilhaume B, Bertagna X, Thomsen M, et al. Transsphenoidal pituitary surgery for the treatment of Cushing's disease: results in 64 patients and long term follow-up studies. J Clin Endocrinol Metab 1988; 66:1056.</a></li><li><a class="nounderline abstract_t">Tahir AH, Sheeler LR. Recurrent Cushing's disease after transsphenoidal surgery. Arch Intern Med 1992; 152:977.</a></li><li><a class="nounderline abstract_t">Jeffcoate WJ, Dauncey S, Selby C. Restoration of dexamethasone suppression by incomplete adenomectomy in Cushing's disease. Clin Endocrinol (Oxf) 1985; 23:193.</a></li><li><a class="nounderline abstract_t">Sonino N, Zielezny M, Fava GA, et al. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 1996; 81:2647.</a></li><li><a class="nounderline abstract_t">Atkinson AB, Kennedy A, Wiggam MI, et al. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 2005; 63:549.</a></li><li><a class="nounderline abstract_t">Streeten DH, Anderson GH Jr, Dalakos T, Joachimpillai AD. Intermittent hypercortisolism: a disorder strikingly prevalent after hypophysial surgical procedures. Endocr Pract 1997; 3:123.</a></li><li><a class="nounderline abstract_t">Benveniste RJ, King WA, Walsh J, et al. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg 2005; 102:1004.</a></li><li><a class="nounderline abstract_t">Locatelli M, Vance ML, Laws ER. Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 2005; 90:5478.</a></li><li><a class="nounderline abstract_t">Jennings AS, Liddle GW, Orth DN. Results of treating childhood Cushing's disease with pituitary irradiation. N Engl J Med 1977; 297:957.</a></li><li><a class="nounderline abstract_t">Johnson DH, Greco FA. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 1986; 58:2198.</a></li><li><a class="nounderline abstract_t">Jagannathan J, Sheehan JP, Pouratian N, et al. Gamma Knife surgery for Cushing's disease. J Neurosurg 2007; 106:980.</a></li><li><a class="nounderline abstract_t">Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 1997; 336:172.</a></li><li><a class="nounderline abstract_t">Minniti G, Osti M, Jaffrain-Rea ML, et al. Long-term follow-up results of postoperative radiation therapy for Cushing's disease. J Neurooncol 2007; 84:79.</a></li><li><a class="nounderline abstract_t">Sheehan JP, Pouratian N, Steiner L, et al. Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg 2011; 114:303.</a></li><li><a class="nounderline abstract_t">Devin JK, Allen GS, Cmelak AJ, et al. The efficacy of linear accelerator radiosurgery in the management of patients with Cushing's disease. Stereotact Funct Neurosurg 2004; 82:254.</a></li><li><a class="nounderline abstract_t">Petit JH, Biller BM, Yock TI, et al. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab 2008; 93:393.</a></li><li><a class="nounderline abstract_t">Mitsumori M, Shrieve DC, Alexander E 3rd, et al. Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 1998; 42:573.</a></li><li><a class="nounderline abstract_t">Lamberts SW, de Jong FH, Birkenhäger JC. Evaluation of a therapeutic regimen in Cushing's disease. The predictability of the result of unilateral adrenalectomy followed by external pituitary irradiation. Acta Endocrinol (Copenh) 1977; 86:146.</a></li><li><a class="nounderline abstract_t">Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84:2664.</a></li><li><a class="nounderline abstract_t">Howlett TA, Plowman PN, Wass JA, et al. Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: long-term follow-up. Clin Endocrinol (Oxf) 1989; 31:309.</a></li><li><a class="nounderline abstract_t">Sharpe GF, Kendall-Taylor P, Prescott RW, et al. Pituitary function following megavoltage therapy for Cushing's disease: long term follow up. Clin Endocrinol (Oxf) 1985; 22:169.</a></li><li><a class="nounderline abstract_t">Dias RP, Kumaran A, Chan LF, et al. Diagnosis, management and therapeutic outcome in prepubertal Cushing's disease. Eur J Endocrinol 2010; 162:603.</a></li><li><a class="nounderline abstract_t">Erfurth EM, Bülow B, Svahn-Tapper G, et al. Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J Clin Endocrinol Metab 2002; 87:4892.</a></li><li><a class="nounderline abstract_t">Brada M, Ashley S, Ford D, et al. Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol (Oxf) 2002; 57:713.</a></li><li class="breakAll">Heavy ion therapy: Alpha particle therapy of pituitary tumors. In: Recent advances in diagnosis and treatment of pituitary tumors, Linfoot, JA (Eds), Raven Press, New York 1979. p.245.</li><li class="breakAll">Kjellberg RN, Kliman B, Swisher B, et al.. Proton beam therapy of Cushing's disease and Nelson's syndrome. In: Secretory tumors of the pituitary gland, Black PML, et al. (Eds), Raven Press, New York 1984. p.295.</li><li><a class="nounderline abstract_t">Burke CW, Doyle FH, Joplin GF, et al. Cushing's disease. Treatment by pituitary implantation of radioactive gold or yttrium seeds. Q J Med 1973; 42:693.</a></li><li><a class="nounderline abstract_t">Cassar J, Doyle FH, Mashiter K, Joplin GF. Treatment of Cushing's disease in juveniles with interstitial pituitary irradiation. Clin Endocrinol (Oxf) 1979; 11:313.</a></li><li><a class="nounderline abstract_t">Lunsford LD, Flickinger J, Lindner G, Maitz A. Stereotactic radiosurgery of the brain using the first United States 201 cobalt-60 source gamma knife. Neurosurgery 1989; 24:151.</a></li><li><a class="nounderline abstract_t">Friedman WA, Bova FJ. The University of Florida radiosurgery system. Surg Neurol 1989; 32:334.</a></li><li><a class="nounderline abstract_t">Höybye C, Grenbäck E, Rähn T, et al. Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 2001; 49:284.</a></li><li><a class="nounderline abstract_t">Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993; 328:87.</a></li><li><a class="nounderline abstract_t">Samaan NA, Schultz PN, Yang KP, et al. Endocrine complications after radiotherapy for tumors of the head and neck. J Lab Clin Med 1987; 109:364.</a></li><li><a class="nounderline abstract_t">Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 1995; 80:2859.</a></li><li><a class="nounderline abstract_t">Barahona MJ, Resmini E, Sucunza N, Webb SM. Diagnosis of cure in Cushing's syndrome: lessons from long-term follow-up. Front Horm Res 2010; 38:152.</a></li></ol></div><div id="topicVersionRevision">Topic 118 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4326256" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Results of treatment in 108 patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37207359" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Current and Future Advances in Surgical Therapy for Pituitary Adenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18196319" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Surgery for Cushing's syndrome: an historical review and recent ten-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2820217" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The diagnostic accuracy of preoperative CT scanning in the evaluation of pituitary ACTH-secreting adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3809493" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cushing syndrome: pituitary CT scanning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8222293" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Comparison of computerized tomography and magnetic resonance imaging for the examination of the pituitary gland in patients with Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3562821" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pituitary adenomas in patients with Cushing disease: initial experience with Gd-DTPA-enhanced MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12679440" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8154641" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7452337" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidental pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6326387" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cushing's syndrome in a patient with suppressible hypercortisolism and an empty sella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7616266" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Intraoperative ultrasound-directed resection of pituitary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15240617" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pituitary magnetic resonance imaging findings do not influence surgical outcome in adrenocorticotropin-secreting microadenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18826366" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19267526" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15473881" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cavernous and inferior petrosal sinus sampling in the evaluation of ACTH-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16219718" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : An assessment of petrosal sinus sampling for localization of pituitary microadenomas in children with Cushing disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23553862" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18797356" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Outcomes after repeat transsphenoidal surgery for recurrent Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7829644" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Isolated hyponatremia after transsphenoidal pituitary surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235676" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2171817" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Transsphenoidal surgery for Cushing's disease: does what is removed determine the endocrine outcome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9007854" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468901" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prevalence, predictors and patterns of postoperative polyuria and hyponatraemia in the immediate course after transsphenoidal surgery for pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10433303" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12161492" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739423" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849241" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Transsphenoidal surgery for Cushing's disease: defining cure and following outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849243" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/625141" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Transsphenoidal removal of pituitary microadenoma in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3001439" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cushing's syndrome: update of diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6847933" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A survey of results with transsphenoidal surgery in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8271020" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Early repeat surgery for persistent Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16234305" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical review: Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7593411" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6321987" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of Cushing's disease in childhood and adolescence by transsphenoidal microadenomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629245" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long term follow-up of transsphenoidal surgery for the treatment of Cushing's disease in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9329338" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470618" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Postoperative testing to predict recurrent Cushing disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10366371" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Long-term mortality after transsphenoidal surgery for Cushing disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579802" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15886242" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671181" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20080848" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Delayed remission after transsphenoidal surgery in patients with Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7862184" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8706280" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Assessment of cure after transsphenoidal surgery for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10913942" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Usefulness of the desmopressin test in the postoperative evaluation of patients with Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182093" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Role for postoperative cortisol response to desmopressin in predicting the risk for recurrent Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11453953" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Desmopressin stimulation test before and after pituitary surgery in patients with Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7354119" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cushing's disease: management by transsphenoidal pituitary microsurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3806203" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Surgical treatment of Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2843068" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Transsphenoidal microsurgery for Cushing disease. A report of 216 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12182435" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6288366" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cushing's syndrome: problems in management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19200645" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Outcome of transsphenoidal surgery for Cushing's disease: a high remission rate in ACTH-secreting macroadenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17961026" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Transsphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8957739" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treatment of Cushing's disease by transsphenoidal, pituitary microsurgery: prognosis factors and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9285597" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11838791" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6273604" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cushing's disease in a patient with an ectopic pituitary adenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7775621" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Extrasellar, intracavernous sinus adrenocorticotropin-releasing adenoma causing Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443699" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Extrapituitary parasellar microadenoma in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636117" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Surgical remission of pituitary adenomas confined to the neurohypophysis in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3360898" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Transsphenoidal pituitary surgery for the treatment of Cushing's disease: results in 64 patients and long term follow-up studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1580725" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Recurrent Cushing's disease after transsphenoidal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4053415" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Restoration of dexamethasone suppression by incomplete adenomectomy in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8675592" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Risk factors and long-term outcome in pituitary-dependent Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16268808" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15251471" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Intermittent hypercortisolism: a disorder strikingly prevalent after hypophysial surgical procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16028758" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15956075" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/909542" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Results of treating childhood Cushing's disease with pituitary irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3756767" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17564168" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Gamma Knife surgery for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988897" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17356896" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term follow-up results of postoperative radiation therapy for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20540596" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15665560" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The efficacy of linear accelerator radiosurgery in the management of patients with Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18029460" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9806517" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/199008" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Evaluation of a therapeutic regimen in Cushing's disease. The predictability of the result of unilateral adrenalectomy followed by external pituitary irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443657" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2559823" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3921294" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pituitary function following megavoltage therapy for Cushing's disease: long term follow up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952125" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Diagnosis, management and therapeutic outcome in prepubertal Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12414846" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460319" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Cerebrovascular mortality in patients with pituitary adenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460319" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cerebrovascular mortality in patients with pituitary adenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460319" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cerebrovascular mortality in patients with pituitary adenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4369894" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cushing's disease. Treatment by pituitary implantation of radioactive gold or yttrium seeds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/509744" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Treatment of Cushing's disease in juveniles with interstitial pituitary irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2645538" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Stereotactic radiosurgery of the brain using the first United States 201 cobalt-60 source gamma knife.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2683164" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The University of Florida radiosurgery system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11504104" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416438" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Hypothalamic-pituitary dysfunction after radiation for brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3819573" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Endocrine complications after radiotherapy for tumors of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7559865" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20616506" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Diagnosis of cure in Cushing's syndrome: lessons from long-term follow-up.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
